hotspot -WSS

hotspot

author：explore 2025-09-30 22:27:49 - browse：9253

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Can Threads overtake X, formerly known as Twitter? Experts weigh in.

WSS

Biden praises World Series champion Astros for impact off the field during White House celebration

Sage's campaign to raise awareness of postpartum depression hits a nerve

Choosing scientific sides in the fight against Alzheimer's

Medical schools are missing the mark on artificial intelligence

Germany receives 178 compensation applications from gay servicepeople over discrimination

Travel bans should be based on evidence, not politics or fear

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Guidelines to prevent youth baseball injuries need more muscle

Does Medicare's free annual wellness visit do any good?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FTX founder Sam Bankman

Hepatitis C has a cure — but many Americans still lack access to it

Rock icon Freddie Mercury pre

Drug repurposing or repositioning? The language matters

Travel bans should be based on evidence, not politics or fear

Heart attack and stroke risk calculators need revising

Does Medicare's free annual wellness visit do any good?

hotspot

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Medical mystery: When an infection after surgery isn’t what it seems

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Judge rejects Trump's counterclaim against E. Jean Carroll

hotspot

hotspot

knowledge

entertainment